Tyra Biosciences, Inc. (NASDAQ:TYRA) Receives Consensus Recommendation of "Buy" from Analysts

Tyra Biosciences, Inc. (NASDAQ:TYRA - Get Free Report) has received a consensus rating of "Buy" from the six brokerages that are presently covering the stock, MarketBeat Ratings reports. Six analysts have rated the stock with a buy rating. The average twelve-month price target among analysts that have issued ratings on the stock in the last year is $30.50.

TYRA has been the topic of a number of recent research reports. Oppenheimer raised their price objective on shares of Tyra Biosciences from $25.00 to $33.00 and gave the company an "outperform" rating in a research note on Thursday, September 19th. HC Wainwright cut their target price on Tyra Biosciences from $32.00 to $30.00 and set a "buy" rating on the stock in a research note on Monday, November 11th. UBS Group started coverage on Tyra Biosciences in a research note on Tuesday. They issued a "buy" rating and a $28.00 price target for the company. Wedbush reiterated an "outperform" rating and issued a $28.00 price target on shares of Tyra Biosciences in a research report on Friday, October 25th. Finally, Bank of America upgraded shares of Tyra Biosciences from a "neutral" rating to a "buy" rating and increased their target price for the stock from $22.00 to $31.00 in a report on Friday, October 18th.

Insider Buying and Selling

In other Tyra Biosciences news, CEO Todd Harris sold 15,394 shares of the business's stock in a transaction that occurred on Thursday, October 17th. The stock was sold at an average price of $25.85, for a total transaction of $397,934.90. Following the transaction, the chief executive officer now owns 1,418,647 shares of the company's stock, valued at $36,672,024.95. The trade was a 1.07 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director Nina S. Kjellson sold 11,078 shares of the stock in a transaction that occurred on Wednesday, October 30th. The shares were sold at an average price of $16.17, for a total value of $179,131.26. Following the completion of the sale, the director now directly owns 472,207 shares of the company's stock, valued at approximately $7,635,587.19. The trade was a 2.29 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders sold 84,160 shares of company stock worth $1,827,047. 15.40% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of TYRA. HighVista Strategies LLC bought a new position in Tyra Biosciences during the second quarter worth about $257,000. Franklin Resources Inc. bought a new position in shares of Tyra Biosciences during the 3rd quarter worth approximately $278,000. Valence8 US LP acquired a new position in shares of Tyra Biosciences during the 3rd quarter worth approximately $310,000. SG Americas Securities LLC bought a new stake in Tyra Biosciences in the 3rd quarter valued at $311,000. Finally, The Manufacturers Life Insurance Company acquired a new stake in Tyra Biosciences during the 3rd quarter valued at $333,000. 84.14% of the stock is currently owned by institutional investors and hedge funds.

Tyra Biosciences Price Performance

Shares of NASDAQ TYRA traded down $0.11 during midday trading on Tuesday, hitting $15.95. The stock had a trading volume of 368,741 shares, compared to its average volume of 237,185. Tyra Biosciences has a fifty-two week low of $11.32 and a fifty-two week high of $29.60. The firm has a market cap of $807.12 million, a P/E ratio of -9.91 and a beta of 1.04. The company's 50-day simple moving average is $15.48 and its 200 day simple moving average is $19.24.

Tyra Biosciences (NASDAQ:TYRA - Get Free Report) last announced its quarterly earnings data on Thursday, November 7th. The company reported ($0.41) earnings per share for the quarter, missing the consensus estimate of ($0.40) by ($0.01). Equities analysts expect that Tyra Biosciences will post -1.57 EPS for the current fiscal year.

About Tyra Biosciences

Tyra Biosciences, Inc, a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions.